TY - JOUR
T1 - Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with bundibugyo ebolavirus
AU - Falzarano, Darryl
AU - Feldmann, Friederike
AU - Grolla, Allen
AU - Leung, Anders
AU - Ebihara, Hideki
AU - Strong, James E.
AU - Marzi, Andrea
AU - Takada, Ayato
AU - Jones, Shane
AU - Gren, Jason
AU - Geisbert, Joan
AU - Jones, Steven M.
AU - Geisbert, Thomas W.
AU - Feldmann, Heinz
N1 - Funding Information:
This work was supported by the National Microbiology Laboratory, Public Health Agency of Canada; the Manitoba Health Research Council (to D. F.); and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
PY - 2011/11/1
Y1 - 2011/11/1
N2 - The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.
AB - The recombinant vesicular stomatitis virus (rVSV) vector-based monovalent vaccine platform expressing a filovirus glycoprotein has been demonstrated to provide protection from lethal challenge with Ebola (EBOV) and Marburg (MARV) viruses both prophylactically and after exposure. This platform provides protection between heterologous strains within a species; however, protection from lethal challenge between species has been largely unsuccessful. To determine whether the rVSV-EBOV vaccines have the potential to provide protection against a newly emerging, phylogenetically related species, cynomolgus macaques were vaccinated with an rVSV vaccine expressing either the glycoprotein of Zaire ebolavirus (ZEBOV) or Côte d'Ivoire ebolavirus (CIEBOV) and then challenged with Bundibugyo ebolavirus (BEBOV), which was recently proposed as a new EBOV species following an outbreak in Uganda in 2007. A single vaccination with the ZEBOV-specific vaccine provided cross-protection (75% survival) against subsequent BEBOV challenge, whereas vaccination with the CIEBOV-specific vaccine resulted in an outcome similar to mock-immunized animals (33% and 25% survival, respectively). This demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on enhancing the immune responses either through booster immunizations or through the inclusion of multiple immunogens.
UR - http://www.scopus.com/inward/record.url?scp=80054742592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054742592&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir350
DO - 10.1093/infdis/jir350
M3 - Article
C2 - 21987745
AN - SCOPUS:80054742592
SN - 0022-1899
VL - 204
SP - S1082-S1089
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - SUPPL. 3
ER -